EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Glucocorticoid Treatment in Severe Asthma

María Florencia Pilia, David Espejo-Castellanos, Christian Romero-Mesones, Xavier Muñoz-Gall, Iñigo Ojanguren-Arranz

Seminars in Respiratory and Critical Care Medicine · 01.02.2026 · 47 (01) · 122-129

DOI: 10.1055/a-2746-4469 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Respiratory and Critical Care Medicine, erschienen am 01.02.2026. Verfasst von María Florencia Pilia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Asthma, Glucocorticoids, Anti-Asthmatic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Fundació Catalana de Pneumologia (FUCAP), Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional (FEDER) and SEPAR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe asthma affects approximately 3% to 10% of the asthmatic population and is characterized by persistent symptoms and frequent exacerbations despite high-intensity therapy. Historically, glucocorticoids (GCs) have been the mainstay of treatment due to their broad anti-inflammatory effects. However, long-term systemic GC use is associated with substantial toxicity and heterogeneous clinical response, largely influenced by underlying inflammatory endotypes. Type 2 (T2) asthma, marked by eosinophilia and cytokines such as IL-4, IL-5, and IL-13, generally responds well to GCs. In contrast, non-T2 phenotypes, often associated with neutrophilic inflammation, obesity, or smoking, exhibit GC resistance. Molecular mechanisms underlying GC resistance include GRβ overexpression, impaired GRα nuclear translocation via mitogen-activated protein kinase (MAPK) activation, and histone deacetylase-2 (HDAC2) inactivation by oxidative stress. Therapeutic strategies for severe asthma involve maximizing inhaled corticosteroids (ICSs) and adding long-acting bronchodilators or biologics before considering maintenance oral corticosteroids (OCSs). Despite these guidelines, OCS overuse remains common, with many patients exposed to cumulative doses associated with severe adverse effects. These include osteoporosis, diabetes, infections, neuropsychiatric symptoms, and adrenal suppression. Therefore, reducing systemic GC exposure is a key objective in modern asthma management. Biologic therapies targeting IgE (omalizumab), IL-5 (mepolizumab, reslizumab), IL-5Rα (benralizumab), IL-4Rα (dupilumab), and thymic stromal lymphopoietin (tezepelumab) have shown substantial OCS-sparing effects in clinical trials, enabling dose reduction or discontinuation in many patients with steroid-dependent asthma. These agents, aligned with precision medicine principles, allow for phenotype-specific treatment and improved safety profiles. Future efforts should focus on improving biomarker-driven treatment selection, expanding non-T2 therapeutic options, and implementing steroid stewardship protocols. In conclusion, while GCs remain essential for acute exacerbations and as bridging therapy, their chronic use should be minimized. Biologic therapies offer a transformative opportunity to reduce GC burden, improving long-term outcomes and quality of life in patients with severe asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaGlucocorticoidsAnti-Asthmatic AgentsHumansAdrenal Cortex HormonesSeverity of Illness Index

Substanzen

GlucocorticoidsAnti-Asthmatic AgentsAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Pneumology Department, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
  • CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
  • Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.

Förderung

  • Instituto de Salud Carlos III
  • Fundació Catalana de Pneumologia (FUCAP), Instituto de Salud Carlos III
  • Fondo Europeo de Desarrollo Regional (FEDER) and SEPAR

Zitieren

APA

Pilia, M. F., Espejo-Castellanos, D., Romero-Mesones, C., Muñoz-Gall, X., & Ojanguren-Arranz, I. (2026). Glucocorticoid Treatment in Severe Asthma. Seminars in Respiratory and Critical Care Medicine, 47(01), 122-129. https://doi.org/10.1055/a-2746-4469

Vancouver

Pilia MF, Espejo-Castellanos D, Romero-Mesones C, Muñoz-Gall X, Ojanguren-Arranz I. Glucocorticoid Treatment in Severe Asthma. Seminars in Respiratory and Critical Care Medicine. 2026;47(01):122-129. doi:10.1055/a-2746-4469

BibTeX
@article{Pilia2026,
  author = {Pilia, María Florencia and Espejo-Castellanos, David and Romero-Mesones, Christian and Muñoz-Gall, Xavier and Ojanguren-Arranz, Iñigo},
  title = {Glucocorticoid Treatment in Severe Asthma},
  journal = {Seminars in Respiratory and Critical Care Medicine},
  year = {2026},
  volume = {47},
  number = {01},
  pages = {122--129},
  doi = {10.1055/a-2746-4469}
}
Kostenlos starten →